NCT04519164CompletedPhase 4
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
This study will evaluate whether the mineralocorticoid receptor antagonist eplerenone, when compared to chlorthalidone plus potassium chloride, can improve cardiac MRI-derived myocardial perfusion reserve and fibrosis, independent of blood pressure, and proportionately to the severity of autonomous aldosterone production.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 79 (actual)
- First submitted
- 17 Aug 2020
- Start date
- 1 Dec 2020
- Primary completion date
- 17 Sept 2025
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Obesity, High blood pressure
- NCT number
- NCT04519164
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 79
- From 1 Dec 2020 to the primary completion date, 17 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known diagnosis or treatment for type 1 or type 2 diabetes
- Known history of CVD (myocardial infarction, heart failure, atrial fibrillation, or stroke)
Lab values
- Serum potassium \> 5.2 mEq/L
Other
- Estimated glomerular filtration rate \< 60 mL/min/1.73m2)
- EKG with ischemic ST-segment or T-wave changes or Q waves in more than one territorial lead or a left bundle branch block
- Pregnancy (verified with a pregnancy test) or breast-feeding
Who the study is looking for
- BMI ≥ 30 with at least one of the following, or BMI ≥ 25 with at least two of the following:
- Untreated Hypertension: Stage I (BP 120-139/80-89 mmHg) or stage II (BP 140-159/90-99 mmHg).
- Treated Hypertension: On one anti-hypertensive medication with BP\<140/90 mmHg and willing to undergo a 2-week washout of the medication before initiating eplerenone or chlorthalidone + KCl
- Dysglycemia: Impaired fasting plasma glucose (100-125 mg/dL) or glycated A1c 5.7-6.4%
- Dyslipidemia: Fasting triglyceride level \> 150 mg/dL and HDL\< 40 mg/dL in men or \<50 mg/dL in women.
- Age between 18 and 70 years old
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.